Vijay Chopra of enochventures.com told CNBC-TV18, "My sense is that Biocon is one of the better placed companies in the entire pharmaceutical pack. They have got fantastic research, they have done some good work in the biosimilar. They have got some good marque products. So it might be a blip on the radar, but I think with a longer term perspective this stock has the potential of reaching Rs 450."
He further added, "I would recommend a hold and I am sure that in a short span once we see some correction in the market, it will come back very strongly. However, just to reiterate, Biocon is one of the best companies I find the pharmaceutical space."